Emerging drugs for the treatment of postsurgical pain.

IF 2.7 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Expert Opinion on Emerging Drugs Pub Date : 2021-12-01 Epub Date: 2021-11-28 DOI:10.1080/14728214.2021.2009799
Esra Kutlu Yalcin, Jorge Araujo-Duran, Alparslan Turan
{"title":"Emerging drugs for the treatment of postsurgical pain.","authors":"Esra Kutlu Yalcin,&nbsp;Jorge Araujo-Duran,&nbsp;Alparslan Turan","doi":"10.1080/14728214.2021.2009799","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Postoperative pain is a distressful experience and remains to be a significant concern after surgery. Current agents either fail to prevent or minimize postoperative pain or cause a series of adverse effects, addiction, or abuse. Opioids have been the gold standard in the treatment of postoperative pain despite their well-described adverse effects. Many new agents with different mechanisms of action have been recently introduced to address this issue.</p><p><strong>Areas covered: </strong>This current review summarizes the list of new and emerging drugs investigated for their efficacy in controlling the postoperative pain and decreasing the need for rescue opioid use, adverse effect profile, abuse, and addiction potential.</p><p><strong>Expert opinion: </strong>Opioids have unrivaled analgesic efficacy. However adverse effects of opioids led to the search for better options. In mild pain most of the emerging drugs have been shown to control postoperative pain and decrease the use of rescue opioid, however fail to control pain after major surgeries causing severe pain. Specific agents such as Oliceridine, new local anesthetics, etc., are effective in controlling severe pain and hold a promise to replace opioids in the near future.</p>","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":"26 4","pages":"371-384"},"PeriodicalIF":2.7000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Emerging Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14728214.2021.2009799","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/11/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 5

Abstract

Introduction: Postoperative pain is a distressful experience and remains to be a significant concern after surgery. Current agents either fail to prevent or minimize postoperative pain or cause a series of adverse effects, addiction, or abuse. Opioids have been the gold standard in the treatment of postoperative pain despite their well-described adverse effects. Many new agents with different mechanisms of action have been recently introduced to address this issue.

Areas covered: This current review summarizes the list of new and emerging drugs investigated for their efficacy in controlling the postoperative pain and decreasing the need for rescue opioid use, adverse effect profile, abuse, and addiction potential.

Expert opinion: Opioids have unrivaled analgesic efficacy. However adverse effects of opioids led to the search for better options. In mild pain most of the emerging drugs have been shown to control postoperative pain and decrease the use of rescue opioid, however fail to control pain after major surgeries causing severe pain. Specific agents such as Oliceridine, new local anesthetics, etc., are effective in controlling severe pain and hold a promise to replace opioids in the near future.

治疗术后疼痛的新兴药物。
术后疼痛是一种痛苦的经历,仍然是术后的一个重要问题。目前的药物要么不能预防或减少术后疼痛,要么导致一系列不良反应、成瘾或滥用。阿片类药物一直是治疗术后疼痛的金标准,尽管它们的不良反应被描述得很好。许多具有不同作用机制的新药物最近被引入来解决这个问题。涵盖领域:本综述总结了在控制术后疼痛和减少阿片类药物使用、不良反应概况、滥用和成瘾潜力方面所研究的新药和新兴药物清单。专家意见:阿片类药物具有无与伦比的镇痛效果。然而,阿片类药物的不良影响促使人们寻找更好的选择。在轻度疼痛中,大多数新兴药物已被证明可以控制术后疼痛并减少阿片类药物的使用,但未能控制大手术后的疼痛,导致严重疼痛。特定的药物如橄榄碱、新型局麻药等,在控制剧烈疼痛方面是有效的,有望在不久的将来取代阿片类药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.90
自引率
0.00%
发文量
28
审稿时长
>12 weeks
期刊介绍: Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on Phase II and Phase III drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信